5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval

In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis...

Source: The Rheumatologist - November 7, 2018 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Analgesics Biologics & Biosimilars Drug Updates Ankylosing spondylitis (AS) FDA oliceridine Pain secukinumab U.S. Food and Drug Administration (FDA) Source Type: research